How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/human-epidermal-growth-factor-2-negative-carcinoma-of-breast.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Human epidermal growth factor 2 negative carcinoma of breast — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Human epidermal growth factor 2 negative carcinoma of breast (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Human epidermal growth factor 2 negative carcinoma of breast, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Verzenio	abemaciclib	Eli Lilly	Kinase inhibitor	Cyclin-dependent kinases 4 and 6 (CDK4/CDK6)	2017-01-01
Ibrance	Palbociclib	Pfizer	CDK4/6 inhibitor	Cyclin-dependent kinases 4 and 6 (CDK4/6)	2015-01-01
Lynparza	olaparib	AstraZeneca	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	Poly [ADP-ribose] polymerase 2	2014-01-01
Lynparza	Lynparza	University of Texas Southwestern Medical Center		Mono [ADP-ribose] polymerase PARP16, Tankyrase-1, Tankyrase-2
PD-0332991	pd-0332991	Pfizer Inc.	PD-0332991, 125mg, 3 cycles	Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase TAO2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AstraZeneca · 1 drug in Human epidermal growth factor 2 negative carcinoma of breast
Eli Lilly · 1 drug in Human epidermal growth factor 2 negative carcinoma of breast
Pfizer · 1 drug in Human epidermal growth factor 2 negative carcinoma of breast
Pfizer Inc. · 1 drug in Human epidermal growth factor 2 negative carcinoma of breast
University of Texas Southwestern Medical Center · 1 drug in Human epidermal growth factor 2 negative carcinoma of breast

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Human epidermal growth factor 2 negative carcinoma of breast:

Cite this brief

Drug Landscape (2026). Human epidermal growth factor 2 negative carcinoma of breast — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/human-epidermal-growth-factor-2-negative-carcinoma-of-breast. Accessed 2026-06-10.

Human epidermal growth factor 2 negative carcinoma of breast full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing